View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, March 21 (HealthDay News) -- Combination therapy of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers is often prescribed without established indications, and is associated with an elevated risk of adverse renal outcomes compared to monotherapy, according to a study published online March 21 in CMAJ, the journal of the Canadian Medical Association.
Finlay A. McAlister, M.D., of the University of Alberta in Edmonton, Canada, and colleagues investigated outcomes in 32,312 new users (mean age, 76.1 years) of either ACE inhibitors or angiotensin-receptor blockers, or a combination of the two between May 2002 and December 2006. Renal outcomes, incidence of hyperkalemia, and stopping treatment within six months of the initial prescription were compared between combination therapy and monotherapy.
The researchers found that, of the 1,750 patients prescribed combination therapy, 86.4 percent did not have trial-established indications. Patients given combination therapy were more likely to have renal dysfunction (adjusted hazard ratio [HR], 2.36) and hyperkalemia (adjusted HR, 2.42). Most patients only took the combination therapy for a median of three months before stopping at least one of the medications.
"Our most striking findings were that combination therapy was commonly prescribed for patients who did not have the trial-proven indications and that it was frequently stopped after only a few months, even when hyperkalemia or renal dysfunction did not occur," the authors write.
One author disclosed financial relationships with Amgen and Merck.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top